Results
Results of included trials. 
Commentary
Although the term croup may colloquially refer to myriad upper respiratory infections in children, the medical literature generally accepts the definition of a viral illness affecting the larynx and trachea (laryngotracheitis). 6 This disease process is common in children, particularly those aged 6 months to 3 years. Diagnosis is clinical and based on symptoms including inspiratory stridor, barking cough, and hoarseness caused by inflammation in the larynx and subglottic airway. 7 Although the viral cause is typically self-limited, croup can cause severe respiratory distress requiring hospitalization, including treatment in an ICU setting. 8 The mainstay of treatment for croup is glucocorticoids. 9 As demonstrated by this meta-analysis, glucocorticoids decrease the severity of croup symptoms at 2 through 24 hours and reduces the risk of return visits and need for hospital admission. The number needed to treat for an additional beneficial outcome to reduce return visits (or readmissions) was 7 (95% CI 5 to 12) for the mean placebo baseline rate of 30.62%.
An important limitation of this meta-analysis was the unclear or high risk of bias in all but one of the included studies. For many studies, this determination was due to inadequate detail in regard to randomization and blinding methodology. Many studies also lacked sufficient detail relating to recruiting and enrollment to assess for the possibility of selection bias. A related issue is the potential for limited generalizability, given that a substantial proportion of the included studies examined inpatients. That said, the overall meta-analysis findings did not change in subgroup analyses stratified by study setting. Next, there was significant heterogeneity across the included studies, as at least one of the following outcomes: changes in croup score; return visits, admissions, or both; hospital length of stay; patient improvement; use of additional treatments; and adverse events. There were no exclusion criteria based on language, publication status, trial conduct, reporting quality, or risk of bias. Two authors independently reviewed the full text of all potentially relevant articles. A third author arbitrated any disagreements in regard to study inclusion.
DATA EXTRACTION AND SYNTHESIS
One author extracted data from each study, whereas a second independently verified extraction to identify errors or omissions. Included studies used alternative croup scores, including the Westley score, 1 the Downes score, 2 or author-created scores. Consequently, the meta-analysis authors calculated treatment effect in regard to croup scores, using a standardized mean difference. They compared the binary outcome of return visits or admissions as a risk ratio with 95% confidence intervals (CIs). For return visits or admissions, authors calculated the number needed to treat for an additional beneficial outcome. Two review authors independently assessed risk of bias for each study by using the Cochrane Risk of Bias Tool, 3 quality of evidence with the Grading of Recommendations Assessment, Development and Evaluation approach, 4 and heterogeneity with the I 2 statistic. 5 They also evaluated treatment effect in subgroup analyses stratifying calculations according to inpatient versus outpatient settings (including the ED), as well as sensitivity analyses.
reflected in the calculated I 2 values. This heterogeneity arose in part from the different scores used by the included studies.
1,2 The use of a croup score in general is a limitation, given that measurements by health care providers can be subjective, with only fair to moderate interrater reliability. 10 The analysis of croup scores in this case was further problematic, given the use of different scores by the included studies, thus requiring the use of standardized mean difference to quantify treatment effect. The clinical relevance of croup score reduction as measured by standardized mean difference is unclear.
According to the results of this meta-analysis, 11 glucocorticoids improve symptoms of croup at 2 through 24 hours and reduce rates of return visits and admissions among young patients with croup.
With data from the 2005 National Hospital Ambulatory Medical Care Survey reporting that only 31% of children presenting to the ED with croup receive glucocorticoids, 12 there exists a need for studies examining potential barriers to this intervention. Given the prevalence of unclear or high risk bias of the included studies, the literature would also benefit from studies evaluating the use of glucocorticoids in croup, with attention to best study practices, including preregistration with full reporting of salient methodology to include recruitment, randomization, and blinding.
